Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 259

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 259
---
 our website. We have included our website address as an inactive textual
reference only.

Insider Trading Arrangements and Policies

During the three months
ended December 31, 2023, none of our directors or officers adopted, amended, or terminated a “Rule 10b5-1 trading arrangement”
or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Our board of directors has
adopted an insider trading policy which governs the purchase, sales, and/or other dispositions of our securities by directors, officers,
and employees. Our insider trading policy is attached hereto as Exhibit 19 and incorporated herein. In addition, we have adopted a Rule
10b5-1 trading plan policy, which permits our officers, directors, and certain other persons to enter into trading plans complying with
Rule 10b5-1 under the Exchange Act. Generally, under these trading plans, the individual relinquishes control over the transactions once
the trading plan is put into place and can only put such plans into place while the individual is not in possession of material non-public
information. Accordingly, sales under these plans may occur at any time, including possibly before, simultaneously with, or immediately
after significant events involving us.

Policy on Trading, Pledging and Hedging of Company Stock

Certain transactions in
our securities (such as purchases and sales of publicly traded put and call options, and short sales) create a heightened compliance
risk or could create the appearance of misalignment between management and stockholders. In addition, securities held in a margin account
or pledged as collateral may be sold without consent if the owner fails to meet a margin call or defaults on the loan, thus creating
the risk that a sale may occur at a time when an officer or director is aware of material, non-public information or otherwise is not
permitted to trade in our securities. Our insider trading policy expressly prohibits derivative transactions of our stock by our executive
officers, directors and employees. In addition, our insider trading policy also expressly prohibits purchases of any derivative securities
that provide the economic equivalent of ownership.

<div align='center'>151

EXECUTIVE COMPENSATION</div>

Except as otherwise specified
in this Executive Compensation section, the information set forth herein relates to the executive compensation paid by Legacy CERo prior
to the Business Combination, and agreements with us, effective as of the Business Combination. PBAX did not